Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33801
Full metadata record
DC FieldValueLanguage
dc.contributor.authorReynolds, Gemma K-
dc.contributor.authorSim, Beatrice-
dc.contributor.authorSpelman, Tim-
dc.contributor.authorThomas, Ashmitha-
dc.contributor.authorLonghitano, Anthony-
dc.contributor.authorAnderson, Mary Ann-
dc.contributor.authorThursky, Karin-
dc.contributor.authorSlavin, Monica-
dc.contributor.authorTeh, Benjamin W-
dc.date2023-
dc.date.accessioned2023-09-27T05:36:37Z-
dc.date.available2023-09-27T05:36:37Z-
dc.date.issued2023-12-
dc.identifier.citationCritical Reviews in Oncology/Hematology 2023-12; 192en_US
dc.identifier.issn1879-0461-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33801-
dc.description.abstractA registered (PROSPERO - CRD42022346462) systematic review and meta-analysis was conducted of all-grade infections amongst adult patients receiving CAR-T therapy for haematological malignancy. Meta-analysis of pooled incidence, using random effects model, was conducted. Cochran's Q test examined heterogeneity. 2678 patients across 33 studies were included in the primary outcome. Forty-percent of patients (95% CI: 0.33 - 0.48) experienced an infection of any grade. Twenty-five percent of infection events (95% CI: 0.16 - 0.34) were severe. Late infections were as common as early infections (IRR = 0.86, 95% CI: 0.38 - 1.98). All-grade infections, bacterial and viral infections were highest in myeloma patients at 57%, 37% and 28% respectively. Patients with NHL more commonly experienced late infections. Pooled rate of invasive candidiasis/yeast infections was 2% in studies utilizing anti-yeast prophylaxis. This review identified a high rate of all-grade infections, moderate rate of severe infections, and myeloma as a high-risk haematological group.en_US
dc.language.isoeng-
dc.subjectCAR-Ten_US
dc.subjectCellular therapiesen_US
dc.subjectInfectionsen_US
dc.subjectLymphomaen_US
dc.subjectMyelomaen_US
dc.titleInfections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleCritical Reviews in Oncology/Hematologyen_US
dc.identifier.affiliationDpartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Infectious Diseases, Austin Health, Melbourne, Victoria.en_US
dc.identifier.affiliationNational Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationInfectious Diseasesen_US
dc.identifier.affiliationDepartment of Infectious Diseases, Barwon Health, Melbourne, Victoria.en_US
dc.identifier.affiliationDepartment of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria.en_US
dc.identifier.doi10.1016/j.critrevonc.2023.104134en_US
dc.type.contentTexten_US
dc.identifier.pubmedid37739146-
dc.description.startpage104134-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Nov 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.